Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03290079
Brief Title: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

First Submitted : September 19, 2017
First Submitted that Met QC Criteria : September 19, 2017
First Posted : September 21, 2017

Last Update Submitted that Met QC Criteria : July 12, 2021
Last Update Posted : July 14, 2021